About Proteovant Therapeutics
Proteovant Therapeutics is a Healthcare company based in King Of Prussia (United States) founded in 2021, and was acquired by SK in June 2023. Targeted protein degrader therapies are developed for cancer and hematology. Its chief executive, as recorded, is Drew Fromkin. Its focus areas include Life Sciences, Hematology, Drugs and Diversified. Its competitors include Keros Therapeutics, Jasper Therapeutics and Disc Medicine; 3 of its 3 listed competitors have raised funding.
Company details
Proteovant Therapeutics was founded in 2021 and is headquartered in King of Prussia, United States. Therapies based on targeted protein degradation are developed for oncology and hematology indications. An AI-driven platform is employed to harness the ubiquitin-proteasome system, by which disease-associated proteins are identified and degraded through the bodys cellular processes. Operations focus on advancing these modalities within the biotechnology sector.
- Headquarters King Of Prussia, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website proteovant.com
- Social LinkedIn
- Acquired by SK (Jun 2023)
Investors in Proteovant Therapeutics
Proteovant Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include SK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on energy, chemical, semiconductor, logistics, and multiple sectors | 1953 | sk.com | Seoul, South Korea |
Investor details for Proteovant Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Proteovant Therapeutics
12 people are tracked at Proteovant Therapeutics (9 in leadership, 3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Drew Fromkin | CEO | Leadership |
Ruby Holder | Chief Strategy Officer | Leadership |
Steven Knight | Senior Director, Medicinal Chemistry | Leadership |
Zhihua Sui | Chief Scientific Officer | Leadership |
Helai Mohammad | VP, Biology | Leadership |
Larry J. Jolivette | VP, DMPK | Leadership |
Corey Strickland | VP, Molecular Technology | Leadership |
Winston Wu | VP, CMC | Leadership |
Pankaj Dwivedi | Assistant Director, Proteomics At Proteovant Therapeutics | Leadership |
Eric Venker | Director | Board & advisors |
Frank Torti | Director | Board & advisors |
Jonggil Choi | Director | Board & advisors |
Complete people profiles for Proteovant Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Proteovant Therapeutics
2 dated milestones of Proteovant Therapeutics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Proteovant Therapeutics is founded.
- Exit Acquired by SK.
Competitors of Proteovant Therapeutics
Proteovant Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Keros Therapeutics, Jasper Therapeutics and Disc Medicine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kerostx.com | 2016 | Lexington, United States | $90M | 136 | Small molecules are developed to treat hematologic and musculoskeletal disorders. | |
| jaspertx.com | 1999 | Redwood, United States | $84.1M | Developer of therapeutics for chronic diseases by targeting mast cells and stem cells | ||
| discmedicine.com | 2017 | Cambridge, United States | $140M | 23 | Developer of therapeutics for the treatment of hematologic diseases |
Detailed competitors of Proteovant Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Hematology
3 companies that operate in the same segment as Proteovant Therapeutics (Hematology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 300 M | 384 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Proteovant Therapeutics
Complete news archive for Proteovant Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Proteovant Therapeutics
Proteovant Therapeutics was founded in 2021.
Proteovant Therapeutics is headquartered in King Of Prussia, United States. It is registered at King Of Prussia, Pennsylvania, United States.
Drew Fromkin is the CEO of Proteovant Therapeutics, as recorded in our data.
Proteovant Therapeutics was founded in 2021 and is headquartered in King of Prussia, United States. Therapies based on targeted protein degradation are developed for oncology and hematology indications. An AI-driven platform is employed to harness the ubiquitin-proteasome system, by which disease-associated proteins are identified and degraded through the bodys cellular processes. Operations focus on advancing these modalities within the biotechnology sector.
Proteovant Therapeutics's top competitors include Keros Therapeutics, Disc Medicine and Jasper Therapeutics.
Proteovant Therapeutics has 1 investor. Key investors include SK.
Yes. Proteovant Therapeutics was acquired by SK in June 2023.